Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) Short Interest Up 193.1% in May

Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) saw a large growth in short interest during the month of May. As of May 29th, there was short interest totaling 3,889 shares, a growth of 193.1% from the May 14th total of 1,327 shares. Based on an average trading volume of 1,517 shares, the short-interest ratio is presently 2.6 days. Currently, 2.3% of the shares of the stock are short sold.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Amplify Weight Loss Drug & Treatment ETF stock. Cravens & Co Advisors LLC acquired a new stake in Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 15,023 shares of the company’s stock, valued at approximately $390,000. Cravens & Co Advisors LLC owned 10.02% of Amplify Weight Loss Drug & Treatment ETF as of its most recent SEC filing.

Amplify Weight Loss Drug & Treatment ETF Stock Performance

Shares of THNR traded down $0.11 during trading hours on Friday, reaching $24.42. The stock had a trading volume of 222 shares, compared to its average volume of 2,050. Amplify Weight Loss Drug & Treatment ETF has a 12 month low of $21.70 and a 12 month high of $27.28. The stock has a market capitalization of $4.15 million, a PE ratio of 24.31 and a beta of 0.40. The company’s 50-day moving average is $24.55 and its two-hundred day moving average is $25.17.

About Amplify Weight Loss Drug & Treatment ETF

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.